| 1 |
NCT02262819 |
Recruiting |
Human Immunity Against Staphylococcus Aureus Skin Infection |
- Staphylococcus Aureus Skin Infection
|
|
Interventional |
Not Applicable |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Evaluate the local in vivo skin immune response to bacteria.
- Evaluate the keratinocyte responses to bacterial challenge.
- Determine if abnormalities in specific immune pathways, such as IL-17 and vitamin D metabolism, are present in subjects with recognized susceptibility to S. aureus infections.
- (and 3 more...)
|
300 |
All |
2 Years to 65 Years (Child, Adult) |
NCT02262819 |
140199
14-I-0199 |
|
October 10, 2014 |
January 1, 2025 |
January 1, 2025 |
October 13, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 2 |
NCT03372941 |
Not yet recruiting |
Hospital Avoidance Strategies for ABSSSI |
|
|
Interventional |
Phase 4 |
- Washington University School of Medicine
- Barnes-Jewish Hospital
- Allergan
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Healthcare utilization related to ABSSSI
- Healthcare cost related to ABSSSI management
- Clinical response
- (and 5 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03372941 |
201709136 |
|
July 1, 2018 |
March 1, 2019 |
October 1, 2019 |
December 14, 2017 |
May 11, 2018 |
|
|
|
| 3 |
NCT03131843 |
Recruiting |
Effectiveness of Alcohol Swabs for Preventing Infections During Vaccination |
|
- Drug: Alcohol
- Drug: No alcohol
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Skin infection
- Skin infection symptoms
- Feasibility of recruitment
- (and 2 more...)
|
170 |
All |
2 Months to 18 Years (Child, Adult) |
NCT03131843 |
33391 |
|
May 1, 2017 |
December 2018 |
December 2018 |
April 27, 2017 |
May 2, 2017 |
|
- Pediatrician Clinic
North York, Ontario, Canada
|
|
| 4 |
NCT02276482 |
Recruiting |
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) |
- Skin Diseases, Infectious
- Skin Diseases, Bacterial
|
- Drug: Tedizolid Phophate 200 mg, IV and/or oral for 6 days
- Drug: Antibiotic comparator
|
Interventional |
Phase 3 |
- Cubist Pharmaceuticals LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs
- Number of Participants with Lesion Reduction Success
- Number of Participants with Investigator's Assessment Indicating Clinical Success
- (and 4 more...)
|
120 |
All |
12 Years to 18 Years (Child, Adult) |
NCT02276482 |
1986-012
TR701-122
2014-004023-40 |
|
March 25, 2015 |
November 7, 2018 |
November 7, 2018 |
October 28, 2014 |
May 17, 2018 |
|
- Call for Information (Investigational Site 0121)
Little Rock, Arkansas, United States - Call for Information (Investigational Site 0119)
Anaheim, California, United States - Call for Information (Investigational Site 0117)
Fountain Valley, California, United States - (and 16 more...)
|
|
| 5 |
NCT02814916 |
Recruiting |
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
- Methicillin-Resistant Staphylococcus Aureus
- Bacterial Infections
- Staphylococcal Skin Infections
|
- Drug: Dalbavancin single dose
- Drug: Dalbavancin two dose
- Drug: Comparator
|
Interventional |
Phase 3 |
- Durata Therapeutics Inc., an affiliate of Allergan plc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with abnormal audiologic assessment
- Change in number of patients with the presence of either Clostridium difficile (CD), vancomycin-resistant enterococci (VRE), or both CD and VRE in bowel flora
- Clinical response
- (and 11 more...)
|
300 |
All |
3 Months to 17 Years (Child) |
NCT02814916 |
DUR001-306
2014-005281-30 |
|
March 30, 2017 |
January 25, 2019 |
January 25, 2019 |
June 28, 2016 |
June 7, 2017 |
|
- University of South Alabama
Mobile, Alabama, United States - Maricopa Integrated Health System
Phoenix, Arizona, United States - Southbay Pharma Research
Buena Park, California, United States - (and 37 more...)
|
|
| 6 |
NCT02566928 |
Recruiting |
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence |
- Methicillin-Resistant Staphylococcus Aureus
- Recurrence
- Staphylococcal Skin Infections
- Antibiotic Resistance
|
- Drug: 2% mupirocin ointment
- Other: Chlorhexidine wash
- Behavioral: Hygiene protocol
|
Interventional |
Phase 4 |
- Clinical Directors Network
- Rockefeller University
- Patient-Centered Outcomes Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- SSTI Recurrence Rate
- Clinical Response Questionnaire
- Subsequent SSTI Self-Report
- (and 9 more...)
|
278 |
All |
7 Years to 70 Years (Child, Adult, Senior) |
NCT02566928 |
CER-1402-10800 |
CAMP-2 |
October 2015 |
November 2018 |
December 31, 2018 |
October 2, 2015 |
July 21, 2017 |
|
- NYU Lutheran Family Health Centers
Brooklyn, New York, United States - NYU Lutheran Medical Center Emergency Department
Brooklyn, New York, United States - Coney Island Hospital
Brooklyn, New York, United States - (and 3 more...)
|
|
| 7 |
NCT03178747 |
Recruiting |
Tzanck Smear With Methylene Blue Stain for Herpes |
- Herpes Simplex
- Herpes Zoster
- Varicella Zoster
|
- Diagnostic Test: Methylene blue
- Diagnostic Test: Giemsa stain
|
Interventional |
Phase 3 |
- Chulalongkorn University
- Dermatological Society of Thailand
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Sensitivity
- Factors that contribute the results from Methylene blue staining
- Specificity
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03178747 |
674/59 |
|
March 7, 2017 |
December 7, 2017 |
March 6, 2018 |
June 7, 2017 |
August 4, 2017 |
|
- Division of Dermatology, Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand
|
|
| 8 |
NCT02582177 |
Not yet recruiting |
Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis |
|
- Drug: Ketoconazole + betamethasone dipropionate
- Drug: Clotrimazole + Dexamethasone acetate
|
Interventional |
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage change in the total score of signs and symptoms
- Mycological cure (Negative result for the direct mycological examination)
- Participants satisfaction regarding the treatment
|
160 |
All |
18 Years to 65 Years (Adult) |
NCT02582177 |
ACH-CND-03(05/15) |
DaVinci |
August 1, 2018 |
January 1, 2019 |
February 1, 2019 |
October 21, 2015 |
April 9, 2018 |
|
|
|
| 9 |
NCT03487549 |
Recruiting |
Cantharidin and Occlusion in Verruca Epithelium |
- Common Wart
- Warts Hand
- Warts
- (and 9 more...)
|
- Drug: VP-102-cantharidin topical film forming solution
- Device: VP-102 Applicator
|
Interventional |
Phase 2 |
- Verrica Pharmaceuticals Inc.
- Instat Consulting, Inc.
- Paidion Research, Inc.
- BioClinica, Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the End of Study Visit.
- Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Visit 2, Visit 3 and Visit 4.
|
20 |
All |
2 Years and older (Child, Adult, Senior) |
NCT03487549 |
VP-102-105 |
COVE-1 |
March 27, 2018 |
October 6, 2018 |
December 8, 2018 |
April 4, 2018 |
April 5, 2018 |
|
- Wake Research Associates
Raleigh, North Carolina, United States
|
|
| 10 |
NCT03207906 |
Recruiting |
A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients |
- Chemotherapy-Associated Paronychia
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Downgrading of the 6-point Paronychia Severity Grading scale (adapted from CTCAE v4.0) in adult cancer patients with chemotherapy-associated paronychia
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03207906 |
2017-VBP-926 |
|
October 24, 2017 |
November 2018 |
December 2018 |
July 5, 2017 |
April 6, 2018 |
|
- Compassionate Cancer Care
Fountain Valley, California, United States - Northwestern University Department of Dermatology
Chicago, Illinois, United States - Washington University
Saint Louis, Missouri, United States - (and 5 more...)
|
|
| 11 |
NCT03059992 |
Recruiting |
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases |
- Invasive Candidiases
- Mucocutaneous Candidiasis
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of Global Response
- Assessment of Recurrence of Baseline Fungal Infection
- Assessment of survival
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03059992 |
SCY-078-301
2017-000381-29 |
FURI |
April 1, 2017 |
September 2019 |
December 2019 |
February 23, 2017 |
April 5, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - UC Davis Medical Center
Sacramento, California, United States - Emory University Hospital Midtown
Atlanta, Georgia, United States - (and 21 more...)
|
|
| 12 |
NCT02629419 |
Recruiting |
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis |
- Candidiasis, Chronic Mucocutaneous
|
|
Interventional |
Phase 2 |
- Matinas BioPharma Nanotechnologies, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Symptoms of mucocutaneous candidiasis
- Area under the plasma concentration versus time curve (AUC)
- Peak Plasma Concentration (Cmax)
- Adverse events, changes in laboratory parameters
|
16 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02629419 |
MB-70004
16-I-0002 |
CAMB |
November 2015 |
June 2018 |
June 2018 |
December 14, 2015 |
December 7, 2017 |
|
- National Institute of Allergy and Infectious Disease (NIAID)
Bethesda, Maryland, United States
|
|
| 13 |
NCT01782131 |
Recruiting |
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) |
|
- Drug: Posaconazole
- Drug: Voriconazole
|
Interventional |
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants Who Died by Week 6
- Number of Participants Achieving Global Clinical Response at Week 12
- Number of Participants Who Died by Week 12
- (and 3 more...)
|
600 |
All |
13 Years and older (Child, Adult, Senior) |
NCT01782131 |
P06200
2011-003938-14
5592-069 |
|
September 25, 2013 |
April 19, 2019 |
July 16, 2019 |
February 1, 2013 |
May 10, 2018 |
|
- Call for Information (Investigational Site 0010)
Birmingham, Alabama, United States - Call for Information (Investigational Site 0127)
Chicago, Illinois, United States - Call for Information (Investigational Site 0250)
Boston, Massachusetts, United States - (and 26 more...)
|
|
| 14 |
NCT02991131 |
Recruiting |
Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study |
- Abscess
- Cellulitis
- Erysipelas
- Wound Infection
|
- Drug: Tedizolid (Sivextro, BAY 11-70438)
- Drug: Linezolid
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The mean number of days that patients are treated in real life in the 2 cohorts consisting of patients treated by 200 mg once daily IV/PO tedizolid or treated by 600 mg twice daily IV/PO linezolid
- Number of participants with adverse events
- Number of participants with investigator-assessed clinical response
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT02991131 |
18299
SX1601 |
DART |
January 13, 2017 |
April 30, 2019 |
August 15, 2019 |
December 13, 2016 |
May 3, 2018 |
|
- Multiple Locations, Colombia
- Multiple Locations, Mexico
- Multiple Locations, Philippines
- (and 4 more...)
|
|
| 15 |
NCT03429595 |
Recruiting |
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo |
|
- Drug: ATx201
- Other: ATx201 GEL Vehicle
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Incidences of Adverse Events and Laboratory Parameters
|
210 |
All |
9 Months to 70 Years (Child, Adult, Senior) |
NCT03429595 |
ATx201-004 |
|
February 23, 2018 |
October 2018 |
December 2018 |
February 12, 2018 |
March 5, 2018 |
|
- AntibioTx Investigational Site
Bloemfontein, South Africa - AntibioTx Investigative Site
Boksburg, South Africa - AntibioTx Investigative Site
Brandfort, South Africa - (and 13 more...)
|
|
| 16 |
NCT03474523 |
Recruiting |
Effectiveness of Diathermy-Radiofrecuency Compared With Cavitation in Cellulitis Treatment |
|
- Other: Experimental group
- Other: Control group
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Decrease in perimeter measures
- Changes in body mass index
- Changes in weight
- (and 2 more...)
|
40 |
Female |
18 Years to 40 Years (Adult) |
NCT03474523 |
Fisioterapia Bahía |
|
October 20, 2017 |
May 22, 2018 |
June 28, 2018 |
March 22, 2018 |
May 3, 2018 |
|
- Faculty of Nursing and Physiotherapy. University of Cadiz
Cádiz, Spain
|
|
| 17 |
NCT02334384 |
Not yet recruiting |
Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess |
|
- Biological: Antimicrobial TheraGauze
|
Interventional |
Phase 1
Phase 2 |
- Eastern Virginia Medical School
- Soluble Systems, LLC
- United States Department of Defense
|
Other / Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
100 |
All |
18 Years to 65 Years (Adult) |
NCT02334384 |
SS-ATG-001 |
|
April 2015 |
October 2018 |
April 2019 |
January 8, 2015 |
January 8, 2015 |
|
- Sentara Norfolk General Hospital
Norfolk, Virginia, United States
|
|
| 18 |
NCT03177993 |
Recruiting |
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji |
- Lymphatic Filariases
- Scabies
- Impetigo
- Soil Transmitted Helminths
|
- Drug: 3 drug dose - IDA
- Drug: 3 drug dose - IDA with second dose of ivermectin
- Drug: 2 drug dose - DA
|
Interventional |
Not Applicable |
- Washington University School of Medicine
- The Task Force for Global Health
- Murdoch Children's Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency, type, and severity of adverse events reported by participants following treatment with triple drug therapy (IDA) and standard two drug therapy (DA) in LF infected and uninfected individuals in a community as measured by CTCAE v4.03
- Clearance of microfilariae (mf) and filarial antigenemia following treatment with IDA or DA in LF infected individuals as measured by microfilaria count in 60ul thick blood smears and filarial test strip rapid diagnostic antigen test.
- Prevalence of scabies in study population measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm
- (and 3 more...)
|
4000 |
All |
Child, Adult, Senior |
NCT03177993 |
201607068-2 |
FIT |
July 13, 2017 |
November 22, 2017 |
November 2018 |
June 6, 2017 |
February 22, 2018 |
|
- Ministry of Health and Medical Services
Suva, Fiji
|
|
| 19 |
NCT01706913 |
Recruiting |
Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis |
|
- Other: Dermatology consult
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Dermatology Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Antibiotic usage
- Length of hospital stay
|
248 |
All |
18 Years and older (Adult, Senior) |
NCT01706913 |
DermFound-2008A058574 |
|
October 2012 |
December 2017 |
December 2017 |
October 15, 2012 |
February 23, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 20 |
NCT02550496 |
Recruiting |
Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis |
|
|
Interventional |
Phase 3 |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The presence of several hair with at least one dermoscopic appearance specific of tinea capitis
- Dermoscopic appearance (corkscrew hair, comma hairs, interrupted (Morse code-like) hairs, hair shafts covered by whitish sheaths, zig-zag shaped hairs) according to microscopic pathogenic species.
- Concordance of dermoscopic appearance for each of the two operators.
- (and 2 more...)
|
100 |
All |
Child, Adult, Senior |
NCT02550496 |
PI2014_843_0019 |
ETDT |
May 2016 |
March 2017 |
March 2017 |
September 15, 2015 |
November 22, 2016 |
|
- CHU Amiens
Amiens, Picardie, France
|
|
| 21 |
NCT03436615 |
Recruiting |
A Study to Evaluate the Safety and Efficacy of SB206 in Children and Adolescents With Molluscum Contagiosum |
|
- Drug: SB206 4%
- Drug: SB206 8%
- Drug: SB206 12%
- Drug: Placebo
|
Interventional |
Phase 2 |
- Novan, Inc.
- Premier Research Group plc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Proportion of Subjects Achieving Complete Clearance at Week 12
- Proportion of Subjects Achieving Complete Clearance at Each Visit
- Time to Complete Clearance
- (and 3 more...)
|
256 |
All |
2 Years to 17 Years (Child) |
NCT03436615 |
NI-MC201 |
|
January 24, 2018 |
October 2018 |
October 2018 |
February 16, 2018 |
February 16, 2018 |
|
- Premier Site# 257
Thornton, Colorado, United States - Premier Site# 116
Newnan, Georgia, United States - Premier Site# 251
Indianapolis, Indiana, United States - (and 9 more...)
|
|
| 22 |
NCT03399955 |
Not yet recruiting |
Short Course Regimens for Treatment of PKDL (Sudan) |
- PKDL - Post-Kala-Azar Dermal Leishmanioid
|
- Drug: Paromomycin
- Drug: Ambisome
- Drug: Miltefosine
|
Interventional |
Phase 2 |
- Drugs for Neglected Diseases
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Definitive Cure
- Incidence of treatment-emergent adverse events
- Pharmacokinetics of Miltefosine
- (and 4 more...)
|
110 |
All |
6 Years to 60 Years (Child, Adult) |
NCT03399955 |
DNDi-MILT COMB-02-PKDL |
|
February 1, 2018 |
February 1, 2021 |
February 1, 2022 |
January 17, 2018 |
January 17, 2018 |
|
|
|
| 23 |
NCT03377803 |
Recruiting |
Cantharidin Application in Molluscum Patients |
|
- Drug: VP-102
- Drug: Placebo
- Device: Applicator
|
Interventional |
Phase 3 |
- Verrica Pharmaceuticals Inc.
- Instat Consulting, Inc.
- Paidion Research, Inc.
- Database Integrations
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit.
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit.
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit.
|
250 |
All |
2 Years and older (Child, Adult, Senior) |
NCT03377803 |
VP-102-102 |
CAMP-2 |
February 14, 2018 |
January 18, 2019 |
February 17, 2019 |
December 19, 2017 |
April 10, 2018 |
|
- Bakersfield Dermatology
Bakersfield, California, United States - Rady Children's Hospital
San Diego, California, United States - Redwood Family Dermatology
Santa Rosa, California, United States - (and 12 more...)
|
|
| 24 |
NCT03377790 |
Recruiting |
Cantharidin Application in Molluscum Patients-1 |
|
- Drug: VP-102
- Drug: Placebo
- Device: Applicator
|
Interventional |
Phase 3 |
- Verrica Pharmaceuticals Inc.
- Instat Consulting, Inc.
- Paidion Research, Inc.
- Database Integrations
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit.
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit.
- Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit.
|
250 |
All |
2 Years and older (Child, Adult, Senior) |
NCT03377790 |
VP-102-101 |
CAMP-1 |
March 21, 2018 |
September 21, 2018 |
October 19, 2018 |
December 19, 2017 |
April 13, 2018 |
|
- Alabama Clinical Therapeutics
Birmingham, Alabama, United States - Southeastern Pediatric Associates
Dothan, Alabama, United States - Applied Research Center of Arkansas
Little Rock, Arkansas, United States - (and 10 more...)
|
|
| 25 |
NCT03349931 |
Recruiting |
Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis |
- Invasive Aspergillosis in Patients With Onco-haematological Diseases
|
- Diagnostic Test: DNA extraction and detection of Aspergillus fumigatus in serum samples
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
- Société ADEMTECH SA
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Performance of PCR for Aspergillosis diagnosis
- Detection of azole resistance
|
420 |
All |
18 Years and older (Adult, Senior) |
NCT03349931 |
K-170102
2017-A01518-45 |
MYCOGENIE |
February 5, 2018 |
April 2019 |
April 2019 |
November 22, 2017 |
May 1, 2018 |
|
- CHU Bordeaux, Groupe hospitalier
Bordeaux, France - CHU de DIJON, Hôpital du bocage
Dijon, France - CHRU de Lille, Hôpital Claude Huriez
Lille, France - (and 3 more...)
|
|
| 26 |
NCT03340597 |
Recruiting |
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects |
|
- Drug: F901318
- Drug: Midazolam
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Incidence of treatment emergent adverse events
- Area under the curve (AUC) 0-tau for F901318
- maximum plasma concentration (Cmax) for F901318
- (and 3 more...)
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT03340597 |
F901318-01-13-17 |
|
December 12, 2017 |
April 2018 |
April 2018 |
November 13, 2017 |
February 15, 2018 |
|
- Covance Clinical Research Unit
Leeds, West Yorkshire, United Kingdom
|
|
| 27 |
NCT03336372 |
Recruiting |
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients |
|
|
Interventional |
Early Phase 1 |
- Center for Clinical Studies, Texas
- LEO Pharma
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete clearance at Week 4
- Partial clearance at Week 4
- Percentage of subjects who sustain complete clearance of MCs in the treatment area at Week 24
- Percentage of subjects who clear MCs outside of the treatment area at Week 24
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03336372 |
IIS-Picato-1386 |
|
December 20, 2017 |
July 1, 2018 |
December 15, 2018 |
November 8, 2017 |
January 26, 2018 |
|
- Center for Clinical Studies
Houston, Texas, United States
|
|
| 28 |
NCT03303898 |
Not yet recruiting |
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - POSTULATE PRIOR TO HUMAN VACCINAL TRIALS Immune Response of Asymptomatic Carriers to L. Infantum |
|
- Procedure: Blood sampling
|
Interventional |
Not Applicable |
- Centre Hospitalier Universitaire de Nice
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- immune response of lymphocytes from asymptomatic carriers
|
30 |
All |
19 Years and older (Adult, Senior) |
NCT03303898 |
17-AOI-04 |
Asymptoleish |
November 10, 2017 |
November 10, 2017 |
March 10, 2019 |
October 6, 2017 |
October 6, 2017 |
|
- Nice Hospital
Nice, France
|
|
| 29 |
NCT03292835 |
Recruiting |
Complex Cutaneous Leishmaniasis Healing Study in Algeria |
|
|
Observational |
|
- K. W. Stahl
- Institut Pasteur
- University of Erlangen-Nürnberg Medical School
- Waisenmedizin e. V. Promoting Access to Essential Medicine
|
Other / Industry |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Lesion Epithelisation
- No healing progress with LeiClean
|
100 |
All |
up to 90 Years (Child, Adult, Senior) |
NCT03292835 |
ALG 17/003 |
LeiClean |
December 3, 2017 |
May 31, 2018 |
September 30, 2018 |
September 26, 2017 |
December 5, 2017 |
|
- EPH Mohamed Boudiaf M'Sila
M'sila, Algeria
|
|
| 30 |
NCT03221075 |
Recruiting |
Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy |
|
|
Observational |
|
- University Hospital of Cologne
- Radboud University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Treatment response to antifungal therapy in patients with an invasive Aspergillosis caused by an azole resistant pathogen.
- Overall survival
|
220 |
All |
Child, Adult, Senior |
NCT03221075 |
17-024 |
CLARITY |
March 1, 2017 |
June 1, 2020 |
July 1, 2020 |
July 18, 2017 |
July 18, 2017 |
|
- University Hospital of Cologne
Cologne, NRW, Germany - Radboud University Nijmegen Medical Center
Nijmegen, Netherlands
|
|
| 31 |
NCT03186378 |
Recruiting |
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. |
|
- Drug: VP-102
- Device: VP-102 Applicator
|
Interventional |
Phase 2 |
- Verrica Pharmaceuticals Inc.
- Paidion Research, Inc.
- Database Integrations
- (and 2 more...)
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Systemic Exposure
- Safety
- Efficacy
- Impact on Quality of Life
|
40 |
All |
2 Years and older (Child, Adult, Senior) |
NCT03186378 |
VP-102-103 |
|
June 8, 2017 |
April 25, 2018 |
May 9, 2018 |
June 14, 2017 |
December 15, 2017 |
|
- Midwest Children's Health
Lincoln, Nebraska, United States
|
|
| 32 |
NCT03129646 |
Recruiting |
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
|
- Drug: Miltefosine
- Drug: Paromomycin
- Drug: Sodium stibogluconate
|
Interventional |
Phase 3 |
- Drugs for Neglected Diseases
- The Netherlands Cancer Institute
- The Institute of Endemic Diseases (IEND), University of Khartoum
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Definitive Cure
- Incidence of Treatment-Emergent Adverse Events
- Efficacy
- (and 3 more...)
|
576 |
All |
4 Years to 50 Years (Child, Adult) |
NCT03129646 |
DNDi-MILT/PM-01-VL |
|
January 24, 2018 |
November 30, 2019 |
November 30, 2019 |
April 26, 2017 |
March 6, 2018 |
|
- University Hospital of Gondar
Gondar, Ethiopia - Kimalel Health Centre
Kimalel, Rift Valley, Kenya - Kacheliba Hospital
Kacheliba, West Pokot, Kenya - (and 3 more...)
|
|
| 33 |
NCT03096457 |
Recruiting |
Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia |
- Leishmaniasis, Cutaneous
- Leishmania Braziliensis Complex
- Leishmaniasis, American
- Leishmaniasis; American, Cutaneous
|
- Drug: Paromomycin Sulfate
- Drug: Pentamidine Isethionate
- Other: Placebo
|
Interventional |
Phase 2
Phase 3 |
- Fundacion Nacional de Dermatologia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change of Lesion size
- Number of participants with treated-related adverse events
|
80 |
All |
12 Years and older (Child, Adult, Senior) |
NCT03096457 |
ABF-BO-2016-102 |
|
April 15, 2017 |
April 15, 2018 |
October 15, 2018 |
March 30, 2017 |
February 7, 2018 |
|
- Hospital Local Palos Blancos
Palos Blancos, La Paz, Bolivia - Hospital Dermatologico de Jorochito
Jorochito, SC, Bolivia
|
|
| 34 |
NCT03073967 |
Recruiting |
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults |
|
- Drug: Pritelivir
- Drug: Foscarnet
|
Interventional |
Phase 2 |
- AiCuris Anti-infective Cures GmbH
- Medpace, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy measured by time to lesion healing
- Efficacy measured by pain rate
- Efficacy measured by time to pain cessation at site of lesion
- (and 19 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03073967 |
AIC316-03-II-01 |
PRIOH-1 |
May 8, 2017 |
March 2019 |
June 2019 |
March 8, 2017 |
April 17, 2018 |
|
- City of Hope National Medical Center
Duarte, California, United States - Yale University School of Medicine - Infectious Diseases
New Haven, Connecticut, United States - Geogetown University Hospital
Washington, District of Columbia, United States - (and 17 more...)
|
|
| 35 |
NCT03067350 |
Recruiting |
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients |
- Invasive Aspergillosis
- Haematological Cancer Patients
- Voriconazole
|
|
Observational |
|
- University Hospital, Grenoble
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- number of initial voriconazole trough plasma concentration in the therapeutic range (1-4mg/l)
- initial voriconazole trough plasma concentrations adjusted on the dose
- number of patients with therapeutic success
- number of patients with adverse effects
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03067350 |
38RC15.168 |
VORIGENE |
January 2015 |
October 2018 |
October 2018 |
March 1, 2017 |
November 17, 2017 |
|
- University Hospital, Grenoble Alpes
Grenoble, France
|
|
| 36 |
NCT03024281 |
Recruiting |
Surveillance of Azole Resistance in Aspergillus Isolates in Taiwan |
|
|
Observational |
|
- National Taiwan University Hospital
- National Health Research Institutes, Taiwan
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Treatment success
- All-cause mortality
- Breakthrough mold infections
- Breakthrough invasive fungal diseases
|
200 |
All |
Child, Adult, Senior |
NCT03024281 |
201605098RIPA |
|
July 2016 |
December 2018 |
December 2018 |
January 18, 2017 |
January 18, 2017 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
|
| 37 |
NCT03023111 |
Not yet recruiting |
Miltefosine and GM-CSF in Cutaneous Leishmaniasis |
|
- Drug: Sbv
- Drug: Miltefosine plus placebo
- Drug: Miltefosine plus GM-CSF
|
Interventional |
Phase 3 |
- Hospital Universitário Professor Edgard Santos
- Oswaldo Cruz Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Final cure rate or complete cicatrization of the ulcer
- Initial cure rate or initial cicatrization of the ulcer
- Healing time
- Clinical and laboratory adverse events
|
300 |
All |
18 Years to 65 Years (Adult) |
NCT03023111 |
Mil GM CL-2017 |
|
March 2017 |
March 2019 |
September 2019 |
January 18, 2017 |
January 20, 2017 |
|
|
|
| 38 |
NCT03014934 |
Recruiting |
Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation |
|
|
Observational |
|
- European Group for Blood and Marrow Transplantation
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Non-relapse mortality
- Relapse free survival
- Overall survival
- (and 3 more...)
|
2100 |
All |
Child, Adult, Senior |
NCT03014934 |
EBMT-8414113 |
IPAT |
January 2016 |
November 2018 |
December 2018 |
January 9, 2017 |
January 20, 2017 |
|
- Charité Universitätsmedizin Berlin
Berlin, Germany - Institute G. Gaslini
Genova, Italy - Clinica di Oncoematologia Pediatrica
Padova, Italy - (and 5 more...)
|
|
| 39 |
NCT03013673 |
Recruiting |
Predicting Visceral Leishmaniasis in HIV Infected Patients |
|
|
Observational |
|
- Institute of Tropical Medicine, Belgium
- University of Gondar, Gondar, Ethiopia
- Medecins Sans Frontieres, Netherlands
- Bureau of Health, Abdurafi, Ethiopia
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prevalence of asymptomatic Leishmania infection
- Incidence rate of asymptomatic Leishmania infection
- Evolution of Leishmania infection markers
- (and 7 more...)
|
1045 |
All |
18 Years and older (Adult, Senior) |
NCT03013673 |
ITM0915 |
PreLeisH |
October 11, 2017 |
May 2021 |
August 2021 |
January 6, 2017 |
April 26, 2018 |
|
- Abdurafi Health Center
Abderafi, Amhara, Ethiopia
|
|
| 40 |
NCT03004092 |
Recruiting |
Novel Biomarkers for Invasive Aspergillosis |
|
|
Interventional |
Not Applicable |
- Universitaire Ziekenhuizen Leuven
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic accuracy of serum bmGT
- Diagnostic accuracy of a combination of serum bmGT and serum GM
- Prognostic value of serum bmGT
- (and 5 more...)
|
226 |
All |
16 Years and older (Child, Adult, Senior) |
NCT03004092 |
S59863 |
|
January 2017 |
December 2019 |
February 2020 |
December 28, 2016 |
May 3, 2018 |
|
- University Hospitals Leuven
Leuven, Belgium
|
|
| 41 |
NCT02912026 |
Not yet recruiting |
Radiolabelled IV and Oral Metabolism Study of F901318 |
|
- Drug: IV F901318
- Drug: Oral F901318
|
Interventional |
Phase 1 |
- F2G Ltd.
- Quotient Clinical
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
10 |
Male |
40 Years to 65 Years (Adult) |
NCT02912026 |
F901318-01-08-16 |
ADME |
June 2017 |
September 2017 |
September 2017 |
September 23, 2016 |
March 7, 2017 |
|
- Quotient Clinical
Nottingham, Nottinghamshire, United Kingdom
|
|
| 42 |
NCT02894008 |
Recruiting |
A Study of a New Leishmania Vaccine Candidate ChAd63-KH |
|
|
Interventional |
Phase 2 |
- University of York
- University of Khartoum
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cellular immune responses
- Clinical changes in cutaneous PKDL disease
|
24 |
All |
12 Years to 50 Years (Child, Adult) |
NCT02894008 |
2016-000369-22 |
Leish2a |
November 2016 |
September 2018 |
December 2018 |
September 9, 2016 |
February 5, 2018 |
|
- Centre for Tropical Medicine
Doka, Gedarif, Sudan
|
|
| 43 |
NCT02841215 |
Not yet recruiting |
Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies |
- Gale
- Severe Forms of Scabies
- Oral Parasitic Drug
- Ivermectin
|
- Drug: Ivermectin 200 µg/kg
- Drug: Ivermectin 400 µg/kg
|
Interventional |
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Rate of a successful treatment defined by : -Two negative parasitologic or two dermoscopic exams
- Rate of a successful treatment defined by : - A clinical response : disappearance of clinical active lesions
- Rate of adverse effects
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT02841215 |
P140939 |
GALECRUSTED |
March 2017 |
March 2019 |
March 2019 |
July 22, 2016 |
December 8, 2016 |
|
- Henri Mondor Hospital
Creteil, France
|
|
| 44 |
NCT02687971 |
Recruiting |
Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ |
|
|
Interventional |
Phase 2 |
- Drugs for Neglected Diseases
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Initial cure rate
- Final cure rate
- Frequency and severity of AEs
|
130 |
All |
18 Years to 60 Years (Adult) |
NCT02687971 |
DNDi-MILT-07-CL |
|
December 2016 |
December 2017 |
March 2018 |
February 23, 2016 |
April 26, 2017 |
|
- Programa de Estudios y Control de Enfermedades Tropicales (PECET), Universidad de Antioquia
Medellin, Colombia - IMT Alexander Von Humboldt
Lima, Peru
|
|
| 45 |
NCT02656797 |
Recruiting |
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis |
|
- Drug: Topical Amphotericin-B 0.4% liposomal gel
|
Interventional |
Phase 2 |
- Soroka University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Complete re-epithelization
- Lesion size
- Skin manifestations
- Evidence of lesihmania infection
|
108 |
All |
18 Years and older (Adult, Senior) |
NCT02656797 |
sor017715ctil |
|
January 30, 2018 |
January 2020 |
January 2021 |
January 15, 2016 |
April 20, 2018 |
|
- Soroka University Medical Center
Beer Sheva, Israel
|
|
| 46 |
NCT02485717 |
Recruiting |
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies |
|
- Drug: spinosad topical suspension, 0.9%
- Other: Placebo
|
Interventional |
Phase 3 |
- ParaPRO LLC
- Concentrics Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Index Subjects Completely Cured of Scabies After a Single Treatment
- Assessing the PK parameters (Cmax, Tmax and AUC 0-12h) of spinosad (Spinosyn A and Spinosyn D) and benzyl alcohol
|
120 |
All |
4 Years and older (Child, Adult, Senior) |
NCT02485717 |
SPN-303-15 |
|
May 2, 2017 |
June 15, 2018 |
July 27, 2018 |
June 30, 2015 |
April 24, 2018 |
|
- Elk Grove Clinical Research
Elk Grove, California, United States - The Chappel Group Research
Kissimmee, Florida, United States - San Marcus Research
Miami, Florida, United States - (and 3 more...)
|
|
| 47 |
NCT02485704 |
Recruiting |
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies |
|
- Drug: spinosad topical suspension, 0.9%
- Other: Placebo
|
Interventional |
Phase 3 |
- ParaPRO LLC
- Concentrics Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants Completely Cured of Scabies After a Single Treatment
|
120 |
All |
4 Years and older (Child, Adult, Senior) |
NCT02485704 |
SPN-304-15 |
|
May 10, 2017 |
July 13, 2018 |
August 24, 2018 |
June 30, 2015 |
May 7, 2018 |
|
- Saint Joseph's Clinical Research
Anaheim, California, United States - Long Beach Clinical Trial Services
Long Beach, California, United States - The Chappel Group Research
Kissimmee, Florida, United States - (and 4 more...)
|
|
| 48 |
NCT02429505 |
Recruiting |
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry |
|
|
Observational |
|
- Knight Therapeutics (USA) Inc
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- number of patients cured
- number of patients with adverse effects
|
25 |
All |
12 Years and older (Child, Adult, Senior) |
NCT02429505 |
IMP 2127-4 |
|
July 2015 |
March 2020 |
March 2021 |
April 29, 2015 |
March 7, 2018 |
|
- Fast Track
North Potomac, Maryland, United States
|
|
| 49 |
NCT02427308 |
Recruiting |
Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry |
- Leishmaniasis or Other Uses of Miltefosine
|
|
Observational |
|
- Knight Therapeutics (USA) Inc
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- number of patients with adverse effects during pregnancy
- number of patients with adverse pregnancy outcome
- number of patients with adverse fetal outcome
|
2 |
Female |
Child, Adult, Senior |
NCT02427308 |
IMP 2127-1 |
|
July 2015 |
March 2025 |
March 2026 |
April 28, 2015 |
March 7, 2018 |
|
- Fast Track
North Potomac, Maryland, United States
|
|
| 50 |
NCT02407782 |
Recruiting |
Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children |
|
- Drug: Ivermectin
- Drug: Permethrin
|
Interventional |
Phase 3 |
- University Hospital, Bordeaux
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Assessment of skin lesions and healing at day 28
- Assessment of skin lesions and healing at day 56
- Assessment of skin lesions and healing at day 28 and 56 in children
- (and 4 more...)
|
502 |
All |
up to 16 Years (Child) |
NCT02407782 |
CHUBX 2011/16 |
SCRATCH |
January 2016 |
September 2017 |
September 2017 |
April 3, 2015 |
June 6, 2016 |
|
- CHU de Bordeaux Hôpital Pellegrin
Bordeaux, Aquitaine, France - CHG de Chalon sur Saône
Chalon sur Saône, Bourgogne, France - CHU de Dijon
Dijon, Bourgogne, France - (and 13 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: